Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time.

Shinya Suzuki, Takayuki Otsuka, Koichi Sagara, Shunsuke Matsuno, Ryuichi Funada, Tokuhisa Uejima, Yuji Oikawa, Junji Yajima, Akira Koike, Kazuyuki Nagashima, Hajime Kirigaya, Hitoshi Sawada, Tadanori Aizawa, Takeshi Yamashita

Journal: Circulation journal : official journal of the Japanese Circulation Society 2012;76(3):755-7

PMID: 22293451

Free Full Text on J-STAGE, Japan Science and Technology Information Aggregator, Electronic View on PubMed

Abstract

BACKGROUND

The distribution of activated partial thromboplastin time (APTT) in nonvalvular atrial fibrillation (NVAF) patients under dabigatran therapy remains to be clarified.

METHODS AND RESULTS

The study population was 196 NVAF patients who were treated with dabigatran in 2011 (126 with 220 mg/day). The APTT values showed a wide distribution among the patients, especially in those with a reduced dose, who seemed to show a high value even in patients without contraindications.

CONCLUSIONS

We found a wide distribution of APTT in NVAF patients under dabigatran treatment. High APTT might help screen for bleeding risks among patients under dabigatran, but requires future investigation.

Address: Department of Cardiology, The Cardiovascular Institute, Tokyo, Japan. [email protected]

DOI: 10.1253/circj.cj-11-1335

Link outs

Free resources

Full Text Sources:

https://joi.jlc.jst.go.jp/JST.JSTAGE/circj/CJ-11-1...

Medical:

https://medlineplus.gov/atrialfibrillation.html

MeSH Terms: Aged, Aged, 80 and over, Atrial Fibrillation, Benzimidazoles, Dabigatran, Dose-Response Relationship, Drug, Female, Hemorrhage, Humans, Male, Middle Aged, Partial Thromboplastin Time, beta-Alanine